111 Capital Makes New Investment in Insmed, Inc. $INSM

Key Points

• 111 Capital has acquired a new stake in Insmed, Inc., purchasing 2,356 shares valued at approximately $237,000 during the second quarter.
• Wall Street analysts are optimistic about Insmed, with several raising their price targets; the consensus target price is currently $149.06 and most analysts rate it as a "Moderate Buy."
• In insider transactions, significant sales were made, with insider Orlov S. Nicole Schaeffer selling 76,520 shares for over $11 million, indicating a 67.73% reduction in their position.

111 Capital purchased a new stake in Insmed, Inc. (NASDAQ:INSM - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 2,356 shares of the biopharmaceutical company's stock, valued at approximately $237,000.

Other large investors have also made changes to their positions in the company. Hilltop National Bank acquired a new stake in Insmed in the 2nd quarter valued at approximately $28,000. ORG Partners LLC boosted its position in shares of Insmed by 220.2% in the second quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 196 shares during the period. Cullen Frost Bankers Inc. grew its stake in shares of Insmed by 164.9% in the first quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 221 shares during the last quarter. NBC Securities Inc. bought a new position in Insmed during the first quarter worth $49,000. Finally, Signaturefd LLC increased its position in Insmed by 60.0% during the first quarter. Signaturefd LLC now owns 867 shares of the biopharmaceutical company's stock worth $66,000 after acquiring an additional 325 shares during the period.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. Stifel Nicolaus raised their price target on shares of Insmed from $121.00 to $145.00 and gave the stock a "buy" rating in a research report on Thursday, August 14th. JPMorgan Chase & Co. lifted their target price on Insmed from $111.00 to $135.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 20th. Truist Financial raised their price objective on Insmed from $126.00 to $139.00 and gave the stock a "buy" rating in a research report on Thursday, August 14th. Leerink Partners upped their target price on Insmed from $100.00 to $115.00 and gave the company an "outperform" rating in a research note on Tuesday, June 10th. Finally, TD Cowen lifted their price target on shares of Insmed from $154.00 to $193.00 and gave the stock a "buy" rating in a research note on Thursday, October 2nd. Nineteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Insmed presently has an average rating of "Moderate Buy" and a consensus target price of $149.06.

Insider Buying and Selling

In other Insmed news, insider Orlov S. Nicole Schaeffer sold 76,520 shares of the company's stock in a transaction on Friday, September 12th. The stock was sold at an average price of $145.45, for a total transaction of $11,129,834.00. Following the transaction, the insider owned 36,461 shares of the company's stock, valued at approximately $5,303,252.45. This represents a 67.73% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Melvin Md Sharoky sold 10,000 shares of the business's stock in a transaction on Friday, September 12th. The stock was sold at an average price of $145.39, for a total value of $1,453,900.00. Following the sale, the director owned 262,675 shares of the company's stock, valued at approximately $38,190,318.25. The trade was a 3.67% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 219,568 shares of company stock valued at $28,305,070. Insiders own 3.00% of the company's stock.

Insmed Stock Up 0.7%

NASDAQ INSM opened at $158.28 on Tuesday. The stock's 50 day simple moving average is $133.59 and its 200 day simple moving average is $99.79. The company has a debt-to-equity ratio of 0.45, a current ratio of 6.68 and a quick ratio of 6.33. Insmed, Inc. has a one year low of $60.40 and a one year high of $160.62. The firm has a market cap of $33.46 billion, a PE ratio of -27.72 and a beta of 1.03.

Insmed (NASDAQ:INSM - Get Free Report) last announced its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share for the quarter, missing analysts' consensus estimates of ($1.30) by ($0.40). The business had revenue of $107.42 million during the quarter, compared to analyst estimates of $104.06 million. Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. The business's quarterly revenue was up 18.9% compared to the same quarter last year. During the same quarter last year, the business posted ($1.94) earnings per share. Insmed has set its FY 2025 guidance at EPS. As a group, sell-side analysts forecast that Insmed, Inc. will post -4.56 earnings per share for the current fiscal year.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

Want to see what other hedge funds are holding INSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insmed, Inc. (NASDAQ:INSM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.